A Certified Reference Material
Features
  • This product is qualified as a Certified Reference Material (CRM) that has been manufactured and tested to meet ISO/IEC 17025 and ISO 17034 international standards
  • This CRM has been characterized by metrologically valid procedures and may be used as a quantitative analytical reference standard
  • Certificate of analysis provides the certified property values and the associated uncertainties, including a statement of metrological traceability for the certified values
  • Bulk material is available for qualified institutions; please contact our sales department for pricing
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Cyclobenzaprine-d3 (hydrochloride) (CRM)

A 1 mg/ml solution in methanol

Item No. 18027

GC-MS (PDF)Safety Data Sheet (SDS) (PDF)
Synonyms
Synonyms
  • MK-130-d3
Technical Information
Formal Name
3-(5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methyl-N-(methyl-d3)propan-1-amine, monohydrochloride
CAS Number
1184983-42-3
Molecular Formula
C20H18D3N • HCl
Formula Weight
314.9
Formulation
A 1 mg/ml solution in methanol
SMILES
CN(C([2H])([2H])[2H])CC/C=C1C2=C(C=CC=C2)C=CC3=C/1C=CC=C3.Cl
InChi Code
InChI=1S/C20H21N.ClH/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20;/h3-6,8-14H,7,15H2,1-2H3;1H/i1D3;
InChi Key
VXEAYBOGHINOKW-NIIDSAIPSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $156

    Add
    Cayman Chemical
    Forensic Lab Guide Wall Posters

    Discover our collection of drug identification, naming, and metabolism posters for your lab. We offer all of our posters at no cost to help support the forensic community.

    REQUEST YOURS
    Product Description

    Cyclobenzaprine-d3 (hydrochloride) (CRM) contains three deuterium atoms at the terminal methyl group. It is intended for use as an internal standard for the quantification of cyclobenzaprine (Item No. 15885) by GC- or LC-mass spectrometry. Cyclobenzaprine is a skeletal muscle relaxant that also has sedative properties.1,2,3 It has been shown to antagonize muscarinic receptors (Kis = 25, 60, and 6 nM for M1, M2, and M3, respectively), serotonin 5-HT2 receptors (Kis = 56 and 330 nM for 5-HT2C and 5-HT2B, respectively), and histamine H1 receptor (IC50 = 20 nM).4,5,6

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Trivedi, R.K., and Patel, M.C. Development of a stability-indicating RP-UPLC method for rapid determination of metaxalone and its degradation products in solid oral dosage form. Sci. Pharm. 80(2), 353-366 (2012).

    2. Chou, R., Peterson, K., and Helfand, M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: A systematic review. J. Pain Symptom Manage. 28(2), 140-175 (2004).

    3. See, S., and Ginzburg, R. Choosing a skeletal muscle relaxant. Am. Fam. Physician 78(3), 365-370 (2008).

    4. Gregori-Puigjané, E., Setola, V., Hert, J., et al. Identifying mechanism-of-action targets for drugs and probes. Proc. Natl. Acad. Sci. USA 109(28), 11178-11183 (2012).

    5. Honda, M., Nishida, T., and Ono, H. Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT2 receptors. Eur. J. Pharmacol. 458(1-2), 91-99 (2003).

    6. Lounkine, E., Keiser, M.J., Whitebread, S., et al. Large scale prediction and testing of drug activity on side-effect targets. Nature 486(7403), 361-367 (2012).